<div id="readability-page-1"><div><p>(MT Newswires) -- Health care stocks were mixed Friday afternoon, with the NYSE Health Care Index easing 0.01% and the Health Care Select Sector SPDR Fund (XLV) adding 0.1%.</p><p> The iShares Biotechnology ETF (IBB) was shedding 0.5%.</p><p> In corporate news, Amgen's (AMGN) Uplizna has received a positive opinion from the European Medicines Agency's human medicines committee recommending its approval for adults with active immunoglobulin G4-related disease, a rare autoimmune disorder with no authorized treatments in the EU. Amgen shares rose past 3%.</p><p> InterCure (INCR) shares were down 1.4% after it said Friday it has agreed to buy medical cannabis brand and technology company Botanico, also known as ISHI, in a two-phase deal valued at about 10% of InterCure's outstanding shares on a fully-diluted basis.</p><p>ARS Pharmaceuticals (SPRY) shares added nearly 1% after the company said its nasal spray Neffy has received regulatory approval in Japan for the emergency treatment of allergic reactions, including anaphylaxis.</p></div></div>

SPRY

<p>醫療保健股票在週五表現參差不齊，紐約證券交易所醫療保健指數下跌 0.01%，而醫療保健精選行業 SPDR 基金上漲 0.1%。安進的 Uplizna 在歐盟獲得了積極的批准意見，推動其股價上漲超過 3%。InterCure 的股價在宣佈收購 Botanico 的交易後下跌 1.4%。與此同時，ARS Pharmaceuticals 的股價在其鼻用噴霧劑 Neffy 獲得日本監管批准後上漲近 1%</p>

行業更新：週五下午，醫療保健類股表現參差不齊